WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206453
CAS#: 891859-12-4
Description: Ceralifimod, also known as ONO-4641, is a next-generation sphingosine 1-phosphate (S1P) receptor agonist selective for S1P receptors 1 and 5. In vitro, ONO-4641 showed highly potent agonistic activities versus S1P receptors 1 and 5 [half maximal effective concentration (EC(50) ) values of 0·0273 and 0·334 nM, respectively]. ONO-4641 decreased peripheral blood lymphocyte counts in rats by inhibiting lymphocyte egress from secondary lymphoid tissues. ONO-4641 prevented relapse of disease in a non-obese diabetic mouse model of relapsing-remitting EAE. ONO-4641 may provide therapeutic benefits in the treatment of multiple sclerosis.
MedKoo Cat#: 206453
Name: Ceralifimod
CAS#: 891859-12-4
Chemical Formula: C27H33NO4
Exact Mass: 435.24096
Molecular Weight: 435.56
Elemental Analysis: C, 74.45; H, 7.64; N, 3.22; O, 14.69
Ceralifimod, purity > 98%, is in stock. The same day shipping out after order is received.
Synonym: ONO-4641; ONO 4641; ONO4641; Ceralifimod
IUPAC/Chemical Name: 1-((6-((2-methoxy-4-propylbenzyl)oxy)-1-methyl-3,4-dihydronaphthalen-2-yl)methyl)azetidine-3-carboxylic acid
InChi Key: QDDQIPUKAXBMBX-UHFFFAOYSA-N
InChi Code: InChI=1S/C27H33NO4/c1-4-5-19-6-7-22(26(12-19)31-3)17-32-24-10-11-25-18(2)21(9-8-20(25)13-24)14-28-15-23(16-28)27(29)30/h6-7,10-13,23H,4-5,8-9,14-17H2,1-3H3,(H,29,30)
SMILES Code: CCCC1=CC=C(COC2=CC(CCC(CN3CC(C(O)=O)C3)=C4C)=C4C=C2)C(OC)=C1
The following data is based on the product molecular weight 435.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Krösser S, Wolna P, Fischer TZ, Boschert U, Stoltz R, Zhou M, Darpo B. Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm. J Clin Pharmacol. 2015 Sep;55(9):1051-60. doi: 10.1002/jcph.513. Epub 2015 May 25. PubMed PMID: 25855155.
2: Gonzalez-Cabrera PJ, Brown S, Studer SM, Rosen H. S1P signaling: new therapies and opportunities. F1000Prime Rep. 2014 Dec 1;6:109. doi: 10.12703/P6-109. eCollection 2014. Review. PubMed PMID: 25580263; PubMed Central PMCID: PMC4251414.
3: Komiya T, Sato K, Shioya H, Inagaki Y, Hagiya H, Kozaki R, Imai M, Takada Y, Maeda T, Kurata H, Kurono M, Suzuki R, Otsuki K, Habashita H, Nakade S. Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis. Clin Exp Immunol. 2013 Jan;171(1):54-62. doi: 10.1111/j.1365-2249.2012.04669.x. PubMed PMID: 23199323; PubMed Central PMCID: PMC3530095.
4: Sanada Y, Mizushima T, Kai Y, Nishimura J, Hagiya H, Kurata H, Mizuno H, Uejima E, Ito T. Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis. PLoS One. 2011;6(9):e23933. doi: 10.1371/journal.pone.0023933. Epub 2011 Sep 8. PubMed PMID: 21931623; PubMed Central PMCID: PMC3169557.
5: Ohno T, Hasegawa C, Nakade S, Kitagawa J, Honda N, Ogawa M. The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling. Biopharm Drug Dispos. 2010 Oct;31(7):396-406. doi: 10.1002/bdd.719. PubMed PMID: 20623701.
